4Ts scoring with hemofiltration or hemodialysis clotting

Perbet S, Goet T, Lebreton A, Sapin AF, Constantin JM. Repeated early hemofiltration filters clotting and heparin-induced thrombocytopenia in ICU. J Clin Monit Comput. 2014. doi:10.1007/s10877-014-9589-z. Warkentin TE. Drug-induced immune-mediated thrombocytopenia—from purpura to thrombosis. N Engl J Med. 2007;356(9):891–3. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin. 2011;27(4):805–23. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759–65. Warkentin TE, Linkins LA. Non-necrotizing heparin-induced skin lesions and the 4T’s score. J Thromb Haemost. 2010;8(7):1483–5. McMahon CM, Cuker A. The 4Ts test in the critically ill: timing is everything. J Crit Care. 2014;29(3):468–9. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160–7. Crowther M, Cook D, Guyatt G, Zytaruk N, McDonald E, Williamson D, Albert M, Dodek P, Finfer S, Vallance S, Heels-Ansell D, McIntrye L, Mehta S, Lamontagne F, Muscedere J, Jacka M, Lesur O, Kutsiogiannis J, Friedrich J, Klinger JR, Qushmaq I, Burry L, Kwaja K, Sheppard JA, Warkentin TE. For the PROTECT collaborators, the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial. J Crit Care. 2014;23(3):470.e7–15. Lanquetot H, Leprince T, Ragot S, Boinot C, Jayle C, Robert R, Macchi L. Antithrombin level and circuit thrombosis during hemofiltration after cardiopulmonary bypass. Intensive Care Med. 2008;34(11):2068–75. Kiser TH, MacLaren R, Fish DN, Hassell KL, Teitelbaum I. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy. 2010;30(11):1117–26. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121(4):535–55. Warkentin TE. Heparin-induced skin lesions. Br J Haematol. 1996;92(2):494–7. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163(20):2518–24. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502–7. Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, Murray PT. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2005;39(2):231–6. Lasocki S, Piednoir P, Aizenberg N, Geffroy A, Benbara A, Montravers P. Anti-PF4/heparin antibodies associated with repeated hemofiltration-filter clotting: a retrospective study. Crit Care. 2008;12(3):R84.